Peptomyc SL
OMO-103 in Phase 1b clinical trial
BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.
Peptomyc logo
MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.
Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".
This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Muñoz at the Hospital Gregorio Marañon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.
About Peptomyc
Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.
Contact Information
Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869
SOURCE: Peptomyc SL
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/770698/Peptomyc-Announces-the-Approval-of-Its-Phase-1b-Trial-Testing-OMO-103-in-Combination-With-Standard-of-Care-in-PDAC-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Motorica Raises €5M to Lead the Generative AI Revolution in Character Animation24.6.2025 14:18:00 CEST | Press release
Trusted by top-tier AAA studios and animators, Motorica delivers production-ready motion synthesis at 200x speed, with no compromise on quality or control STOCKHOLM, SE / ACCESS Newswire / June 24, 2025 / Motorica, the global pioneer in Generative AI for character animation and motion synthesis, today announced the close of a €5 million seed funding round, led by Angular Ventures, with participation from Luminar Ventures. The funding will support Motorica's rapid expansion, scaling of its proprietary AI platform and continued investment in R&D to shape the future of instant character animation. Motorica's technology is already being used in live production environments by world-leading AAA studios to deliver production-ready animation at unprecedented speed and scale. In early deployments, studios have reported up to a 99% reduction in animation time, achieving animation workflows that are 200x faster than the traditional motion capture to gameplay animation workflow - without sacrific
MTN to Lead Europe's Future of Connectivity and Network Solutions from New European HQ in Paris, France24.6.2025 12:30:00 CEST | Press release
PARIS, FRANCE AND FT. LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / MTN, a fully owned subsidiary of FMC GlobalSat and the world's leading provider of converged satellite and wireless connectivity solutions, announced the opening of its new European headquarters in Paris, France. This move significantly expands the company's footprint in the region and enhances its operational capabilities, deepening its commitment to serve clients across the European market and beyond. Just a few minutes away from Place de La Madeleine, MTN located its new hub in Boulevard Malesherbes, right in the fast and busy heart of Paris. MTN is committed to establishing a center of excellence in the city, creating 50 highly skilled new positions initially and planning a multimillion-dollar investment in France. These roles will primarily focus on software development, IT, and engineering, reinforcing the company's commitment to innovation and technical expertise. Currently, MTN serves numerous French compa
Global Financial Institutions and Technology Leaders Collaborate Under FINOS to Launch Open Source Common Controls for AI Services24.6.2025 10:00:00 CEST | Press release
BMO, Citi, Microsoft, Morgan Stanley, RBC, Google Cloud, Red Hat, AWS and others join forces to set secure, standardized AI controls for financial services NEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / The Fintech Open Source Foundation (FINOS), part of the Linux Foundation, today announced the launch and cross-industry support behind its Common Controls for AI Services initiative - a collaborative effort to define standardized open source technology-neutral controls for safe and compliant AI adoption in the financial industry. Global financial institutions - including BMO, Citi, Morgan Stanley, RBC, are working with major cloud and technology providers, including Microsoft, Google Cloud and Amazon Web Services (AWS). These efforts are supported by consultants and vendors like Red Hat, Sonatype, ControlPlane, Scott Logic and Tetrate, working collaboratively to develop baseline AI controls tailored to the complex regulatory and operational requirements of the financial sector. W
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology23.6.2025 15:00:00 CEST | Press release
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows. As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps. "The ongoing H5N1 pandemic highlighted the urgent need
Geneva, Switzerland Set to Host World of Coffee Welcoming Thousands of Specialty Coffee Professionals and Enthusiasts23.6.2025 08:00:00 CEST | Press release
Trade Show and Conference to Feature Four Global Competitions and Much More GENEVA, SWITZERLAND / ACCESS Newswire / June 23, 2025 / The Specialty Coffee Association (SCA) is excited to welcome the global coffee community to World of Coffee Geneva, taking place June 26-28, 2025 at Palexpo SA. As Europe's premier international specialty coffee trade show, this year's event promises a dynamic schedule filled with inspiring workshops, prestigious global competitions, and engaging experiences designed to educate, connect, and energize coffee professionals from around the world. "We are thrilled to welcome the global coffee community to World of Coffee Geneva, opening June 26 in Switzerland, one of the most active European countries in the global specialty coffee industry and value chain," said Yannis Apostolopoulos, CEO of the Specialty Coffee Association. "Geneva is the perfect host city for bringing together industry leaders, entrepreneurs, and coffee lovers from around the world. We look
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom